Our Brands · Therapy Pillar
Hyperuricemia & Gout in CKD
Hyperuricemia is both a marker and a driver of CKD progression. In Asian patients, allopurinol carries a known HLA-B*5801 hypersensitivity risk; febuxostat - without the need for HLA testing and with simpler renal dosing - is preferred in most CKD-aware practices. Nixura® is our febuxostat brand, dosed for the Indian renal population.
Brands in this pillar
1 brand in this pillar.
For Healthcare Professionals
Detailed prescribing information, dosing guidance and clinical references are available on each brand page. Speak to our Medical Information team for HCP-only support.